EN DE
STOCK COMPARISON

Hunan Hansen Pharmaceutical Co vs Merck KGaA: Fair Value & Quality

Both stocks run through our valuation models. Here is how Hunan Hansen Pharmaceutical Co (002412) and Merck KGaA (MRK) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees Hunan Hansen Pharmaceutical Co as the less overvalued of the two: Hunan Hansen Pharmaceutical Co trades at ¥9.10 versus a fair value of ¥7.51 (-17%), while Merck KGaA trades at €134 versus €109 (-19%).
Hunan Hansen Pharmaceutical Co
002412.SHE · CNY · Health Care
-17%
upside to fair value
overvalued
Price¥9.10
Fair Value¥7.51
Quality72/100
Merck KGaA
MRK.XETRA · EUR · Health Care
-19%
upside to fair value
overvalued
Price€134
Fair Value€109
Quality62/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Hunan Hansen Pharmaceutical CoMerck KGaA
Valuation
20.2×P/E (TTM)24.1×
0.66×P/S (TTM)3.16×
0.29×P/B2.32×
1.8×EV/EBITDA13.0×
n/aPEG2.76×
−17.5%Fair value upside−18.9%
3.3%Dividend yield1.6%
¥0.30Dividend per share€2.20
Profitability
22%Operating margin18%
1.45×EBIT margin trend (5Y)1.07×
10%Return on equity9%
5%Return on assets5%
Growth
-2%Revenue growth (YoY)-3%
4.3%Avg. growth/yr (3Y)-1.7%
7.0%Avg. growth/yr (5Y)3.8%
+11.3%Value creation/yr+7.2%
Balance & size
145.5×Interest coverage (EBIT/interest)15.5×
0.02×Debt / equity0.36×
$683MMarket cap$66B
healthyGrowth qualitymixed

Hunan Hansen Pharmaceutical Co leads: 14 to 0 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Hunan Hansen Pharmaceutical Coof which business quality 71 · market factors 78 Merck KGaAof which business quality 61 · market factors 66
ProfitabilityMargins and returns on capital today
49
41
Quality GrowthAre margins and returns improving?
48
40
CashflowEarnings quality: real cash, not paper profit
81
57
Fin. StrengthBalance sheet, leverage, solvency risk
86
76
InvestmentDisciplined investing over empire-building
78
80
Low VolatilityCalm price path (market factor)
62
72
MomentumPrice trend over the last 3–12 months (market factor)
100
61
52W MomentumDistance to the 52-week high (market factor)
60
68
Net IssuanceShare count: buybacks or dilution?
82
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyHunan Hansen Pharmaceutical CoPrice ¥9.10Merck KGaAPrice €134
DCF Models-22%below the price¥7.07-20%below the price€107
Earnings-Based-64%below the price¥3.30-60%below the price€53.25
Dividend Discount-100%below the price¥0.05-70%below the price€40.71
Multiples-18%below the price¥7.49-12%close to the price€118
Asset-Based-65%below the price¥3.17-67%below the price€44.06
Growth DCF-27%below the price¥6.68-29%below the price€94.57
Economic Profit-56%below the price¥4.04-50%below the price€66.44
Growth Earnings-17%below the price¥7.51-14%close to the price€115
Minimum-100%below the price¥0.05-70%below the price€40.71
Maximum-17%below the price¥7.51-12%close to the price€118
Median-41%below the price¥5.36-40%below the price€80.50
Geometric mean-68%below the price¥2.90-45%below the price€73.75

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Hunan Hansen Pharmaceutical Co: 26 of 26 models see the stock below the current price.

Merck KGaA: 23 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Hunan Hansen Pharmaceutical Co
Price ¥9.10
Fair Value ¥7.51
Bear ¥5.17Bull ¥9.77
Merck KGaA
Price €134
Fair Value €109
Bear €59.91Bull €150

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Hunan Hansen Pharmaceutical Co · Health Care

Quality score72 · Top 25%
Fair value upside-17% · above median

Merck KGaA · Health Care

Quality score62 · above median
Fair value upside-19% · above median

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees Hunan Hansen Pharmaceutical Co as the less overvalued of the two: Hunan Hansen Pharmaceutical Co trades at ¥9.10 versus a fair value of ¥7.51 (-17%), while Merck KGaA trades at €134 versus €109 (-19%).

Hunan Hansen Pharmaceutical Co has the higher quality score (72/100).

Open Hunan Hansen Pharmaceutical Co live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.